We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Medica 2024 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Mast Group Appointed European Distributor of Kanto Tests

By Labmedica staff writers
Posted on 14 Nov 2006
The Kanto Chemical Company (Tokyo, Japan) has appointed Mast Group Ltd. (Merseyside, UK) as its authorized representative and exclusive European distributor for a range of tests for extended-spectrum beta-lactamase (ESbL) detection.

The Cica Beta products of Kanto incorporate the use of a novel chromogenic compound to differentiate between the various beta lactamase enzymes and permit confirmation of an organism as an ESbL, metallo-beta lactamase (MBL), or AmpC-type lactamase producer. Separate kits are available for each type of beta lactamase enzyme and each kit is color coded for simple identification. The kits can be used individually or in combination for comprehensive enzyme profiling.

Lactamase-producing strains of bacteria are more resistant to antibiotics and cause infections that are difficult to treat. In many instances, only two oral antibiotics and a very limited group of intravenous antibiotics are effective.

Suspect bacterial colonies are streaked onto each strip and identification is made by a clear color change from yellow to red. Results are available within 15 minutes, permitting rapid and accurate identification. The Cica Beta tests supplement the existing range of Mast's identification and antibiotic sensitivity products.

The Cica Beta kits rapidly detect enzyme production in Gram-negative isolates from patients with severe infection. ESbL production by a total of 304 strains of Klebsiella spp., Escherichia coli, and Proteus mirabilis was tested by a Cica Beta kit as well as the phenotypic confirmatory disk test (using cefotaxime and ceftazidime, with and without clavulanate). The kit showed 95.5% and 98.1% sensitivity and specificity, respectively, as compared to the disk test, and thus proved to be an appropriate tool for the rapid detection of ESbL.



Related Links:
Kanto Chemical
Mast Group

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Automated Blood Typing System
IH-500 NEXT
New
Urine Strips
11 Parameter Urine Strips
New
Anti-Secukinumab ELISA
LISA-TRACKER anti-Secukinumab

Latest Industry News

Bio-Techne and ALZpath Partner to Advance Neurodegenerative Disease Research and Treatment

Microbiologics Acquires Diagnostic Quality Controls Manufacturer SensID

Beckman Coulter Partners with BioPorto for Global Distribution of Acute Kidney Injury NGAL Tests